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Six hundred and ninety three male inmates from three penitentiaries, two (A and B) maximum-secu-
rity systems and one (C) minimum-security facility, located in Campinas, State of São Paulo, Brazil were
studied for the presence of human immunodeficiency virus (HIV) antibodies, using a cross-sectional
design. The search for anti-HIV antibodies in 693 samples of sera collected was carried out by two
serological tests: (a) the Microparticle enzyme immunoassay-HIV-1 and HIV-2 (MEIA) (Abbott Labo-
ratories) and (b) the Western Blot-HIV-1 (WB) (Cambridge Biotech Corporation) to confirm positive
results with MEIA. Sera reactivity for HIV antibodies was 14.4%. The highest frequency of anti-HIV
antibodies was found in the A and B maximum-security prisons: 17% and 21.5%, respectively. In prison
C, the frequency of reagents was 10.9%. Seventy three inmates, initially negative in the MEIA test, were
checked again five and seven months later. Three of them, all from the maximum-security facilities,
became reactive in the MEIA test, with confirmation in the WB, suggesting that serological conversion
had occurred after imprisonment.
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 Available literature regarding reported records
since 1985 of anti-human imunodeficiency virus
(anti-HIV) antibodies among jail inmates is incom-
plete. Most works including high number of pris-
oners were carried out in Scotland (Bird et al.
1995), and United States of America (Hoxie et al.
1990, Vlahov et al. 1991) showing, with slight dif-
ferences, that the frequencies of human immuno-
deficiency virus (HIV) positive  reactions were
higher among prisoners than in the normal popu-
lation, excluding those groups, which are under risk
factors pressures (Stark et al. 1995, Carvalho et al.
1996, Zapiola et al. 1996).
Reports about the frequencies of HIV antibod-
ies among prisoners in South America are rare and
include mainly studies on either low number of
prisoners (Jabatur et al. 1991, Veronesi et al. 1993)
or prisoners with manifested acquired immunode-
ficiency syndrome (Aids) (Veronesi et al. 1993).
Taking into consideration several risk factors
to which male inmates are exposed nowadays
(Benezech et al. 1987, Ferrante et al. 1987, Carbajal
et al. 1991, Bird et al. 1995, Calzavara et al. 1995,
Stark et al. 1995, Carvalho et al. 1996), the main
objectives of this study were: (1) to determine the
prevalence of HIV antibodies among sera from 693
inmates of the Penitentiary Complex of Campinas,
SP, Brazil, from January to August 1995, as de-
tected by an immunoenzymatic assay and the West-
ern blotting, using a cross-sectional design; (2) to
compare the influence of the penitentiary system
policy, maximum-security (A and B)  or minimum-
security  (C) on the infection rates and (3) to verify
whether serological conversion has occurred
among the inmates within the study period, as well
as, if age range could affect HIV infection.
MATERIALS AND METHODS
This study was performed with the approval of
the Ethical Committee of the enrolled institutions
and the agreement of all inmates included in this
survey.
Sera samples from prisoners and controls were
collected using 10 ml-vacuum container vials, la-
This study was supported by grants provided by Serviço
Unificado de Saúde, Conselho Nacional de Desenvol-
vimento Científico e Tecnólogico (CNPq) and Fundação
de Amparo à Pesquisa do Estado de São Paulo.
+Corresponding author. Fax: +55-11-818-7354. E-mail:
apestana@icb.usp.br
Received 5 October 1998
Accepted 20 April 1999
480 HIV Seroprevalence in Brazilian Inmates • Neusa Maria Osti et al.
beled with the full names of the individuals in or-
der to avoid any kind of contamination of the lab
or devices, following Centers for Disease Control
and Prevention (CDC) recommendations for pro-
cessing blood and other human specimens contami-
nated by HIV (CDC 1983, 1987a, b).
After clotting, the samples of blood were cen-
trifuged at 3,000 rpm for 10 min and the sera were
then carefully transferred to Khan’s tubes, with
appropriate caps and identification labels. When
sera were not examined on the same day, the tubes
were stored at -18°C, up to testing.
In this study two types of test kits were used
for searching anti-HIV -1/2 antibodies: (a) the
Microparticle Enzyme Immunoassay (MEIA), 3rd
generation (Abbott Laboratories, Illinois, USA),
as a screening test and  (b) the Western Blot   (WB),
(Cambridge Biotech Corporation, Worcester, USA)
to confirm the positive results in the MEIA tests.
To perform the MEIA test the IMx System from
Abbott Laboratories was used, following all the
instructions of the manufacturers. The results were
considered positive for those sera whose relation-
ship between sample reading and “index” reading
was higher than 1,000. Results between 0,900 and
1,100 were indeterminate and those with less than
0,900 were negative.
The WB tests used as a confirmation assay were
also conducted according to the recommendations
of the manufacturers. The controls showed reac-
tivity for the following bands, corresponding to the
antigenic proteins of HIV-1-strong positive con-
trol: p17, p24, p31, gp41, p55, p66, gp120 and
gp160; weak positive control: p24 and gp160;
negative control: no visible band.
The analysis of the results of the WB assays
were performed following the standards established
by  “The Centers for Disease Control and Preven-
tion (CDC)”/Association of State and Territorial
Public Health Laboratory Directors (ASTPHLD)
with slight modifications as recommended by the
kit manufacturers. Briefly, when the band inten-
sity was less than the p24 weak control, the grade
of reactivity was considered +/-; when the band
intensity was stronger than the weak p24 positive
control, but less intense than the strong p24 con-
trol, the grade of reactivity was read as +, and when
the band intensity was greater than the strong p24
control, the grade of reactivity was considered ++.
Overall, the examined sera were considered posi-
tive in the WB for the presence of anti-HIV anti-
bodies when the reactivity grade was either + or
++ and at least two of the following bands had to
be present: gp160, gp120, gp41 or p24. The re-
sults were read as indeterminate when the grade of
reactivity was +/- and negative when no bands were
visible.
Two hundred and two control sera from volun-
teers whose physical examination did not show any
Aids-compatible symptoms and did not belong to
any known risk group for this disease were col-
lected.
All the results were statistically evaluated by
the Epi Info version 6.0, from October 1994, de-
veloped by CDC and kindly provided by the De-
partment of Preventive Medicine and Epidemiol-
ogy, from the College of Medical Sciences, of the
University of Campinas, SP, Brazil.
RESULTS
One hundred out of 693 sera samples were posi-
tive for anti-HIV-1 and HIV-2 antibodies: 45, 17
and 38 for the penitentiaries A, B and C, respec-
tively. None of  202 sera samples from the control
population were positive for anti-HIV antibodies,
as detected by the MEIA test. Only one serum
sample from this group gave an index of 1.123,
which was considered indeterminate (data not
shown).
The percentage of positive results for anti-HIV
antibodies among inmates, detected by the MEIA
test, was significantly higher in the maximum-se-
curity penitentiaries (A and B), with a total of 62
(18.1%) reactive inmates whereas in the Detention
Center (C) 38 (10.9%) individuals were positive
for anti-HIV antibodies by the screening test
(Table).
All positive sera in the MEIA test were then
examined by the WB for the confirmation of the
TABLE
Prevalence of anti-human immunodeficiency virus
(anti-HIV) antibodies in two samples of inmates from
high to minimal security penitentiaries from
Campinas, SP, Brazil
 Anti-HIV antibodies
Type of prison Positive Negative Total
No.  % No.  %
High security 62 18.1 281 81.9 343
(A + B)
Minimal 38 10.9 312 89.2 350
security  (C)
Total 100 14.4 593  85.6 693
Penitentiaries A and B were maximum-security facilities
whereas penitentiary C was minimal security.
Microparticle enzyme immunoassay (MEIA) 3rd
generation (Abbott Laboratories, Illinois, USA)
performed in the IMX System was used for the detection
of anti-HIV antibodies in inmates’ sera, following
manufacturers’ instructions. The results were considered
positive for those sera whose ratio of the sample over
the reading of the “index” was higher than 1.000.
(A+B x C) p=0.006854(S);  OR= 1.81 ( 1.15<OR< 2.86)
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results obtained by the former test. Ninety-seven
out of 100 positive samples by the MEIA test were
positive in the WB for HIV antibodies, one was
negative and two were considered indeterminate.
Figure shows some of the results obtained in the
WB test. Among the control population, the sample
of serum, which gave indeterminate result, when
tested by the MEIA test, was negative by the WB
technique (data not shown).
The frequency of anti-HIV antibodies with re-
gard to the range between 18 and 68 years of age
when 10-year intervals were taken was determined.
It was observed that as far as inmates from the three
studied penitentiaries were concerned, there was
no significant influence of age on the frequency of
seropositivity for HIV, suggesting that while in
prison, independent of age, all the prisoners were
submitted to the same risk factors, increasing the
chances of all of them becoming infected by HIV,
even the eldest ones (data not shown).
Among 73 inmates who were negative in the
first MEIA test, which was performed in the be-
ginning of our research, new samples of sera were
collected to follow-up the evolution of the HIV
infection within the penitentiaries studied. Three
sera, all from penitentiaries A and B (maximum-
security) became positive in the second test by
MEIA, and the results were confirmed by the WB
(data not shown).
DISCUSSION
Comparing the results obtained from prisoners
located in maximum-security penitentiaries (A +
B) with those for penitentiary C (minimum-secu-
rity), the frequency of anti-HIV antibodies was sig-
nificantly higher in the former system (p =
0.006854) demonstrating that the penitentiary sys-
tem of maximum-security, due to the higher risk
factors that the inmates are prone to, may result in
a more pronounced HIV infection rate in this peni-
tentiary system. On the other hand, no significant
difference was observed in the frequencies of anti-
HIV antibodies between the penitentiaries of maxi-
mum-security system, A x B (p = 0.36467).
The risk factors of contamination by HIV exis-
tent in such prisons are usually: (1) spontaneous
or forced homosexual activities; (2) heterosexual
practices without preservatives during intimate vis-
its; (3)  possibility of the use of injected drugs with
the use of common non sterilized syringes and
needles; (4) accidents with contaminated blood dur-
ing rebellions and prison overpopulation, being
even greater in prisons of maximum safety
(Benezech et al. 1987, Ferrante et al. 1987, Carbajal
et al. 1991, Bird et al. 1995, Calzavara et al. 1995,
Stark et al. 1995, Carvalho et al. 1996). In this re-
clusion system the inmates are confined during the
whole period of sentenced jail time, different from
the minimum safety’s prisons, where the inmates
possess activities and are allowed to work outside
the prisons. This fact promotes the development
of habits, which differentiates between these two
types of inmates. It decreases the time of coexist-
ence among the inmates and the time of stay in the
prison, all which render a smaller the risk of con-
tamination mainly by HIV.
Observing the influence of age, taking a 10-
year interval, we did not get any significant age
influence with regard to the frequencies of anti-
HIV antibodies in inmates between the ages of 18
and 59 (p = 0.62878), suggesting that within the
prisons, age did not influence HIV seropositivity.
Conversely, if we look at a report by the Brazilian
Ministry of Health (1995), ranging between the
Examples of positive results for anti-human immunodeficiency
virus  obtained from samples of inmates’ sera by Western Blot.
25: strong positive control; 26: weak positive control; 27: nega-
tive control. Sera 2, 13, 24, 23, 3, 6 and 8 were positive for anti-
HIV antibodies by the WB.
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period of 1980 to 1995, we realize that anti-HIV
antibodies in the general population were more
prevalent among those male persons who were
sexually active around the ages of 25-29 and 30-
34, 12,418 (21.2%) and 13,184 (22.5%), respec-
tively. In the same report, the mean frequency of
1.9% (1,903 cases/15 years) was observed in male
individuals between the ages of 55 and 59.
The published references about HIV infection
and the search for anti-HIV antibodies in our peni-
tentiaries are very poor. Some of the studies were
performed with inmates with overt disease
(Veronesi et al. 1993) (95.1%), and thus the per-
centage of positive results for HIV antibodies was
high. In this latter study, the authors also exam-
ined about 100 inmates from a small prison in the
city of Mogi das Cruzes, State of São Paulo, Bra-
zil, and found 7.5% of individuals positive for anti-
HIV antibodies. Another research carried out in
the Public Jail of Londrina, State of Paraná, Brazil
(Jabatur et al. 1991), reported 6.4% positive re-
sults for anti-HIV antibodies among 158 prison-
ers. However, the situation in 1991 with regard to
jailing conditions in small cities were quite differ-
ent from those in 1995 and also quite different from
the penitentiary complex of Campinas. So, no com-
parison was valid concerning those data.
If we look at the international literature, it is
found that the images, with some variations, are
almost the same as ours, but most of them took
samples of sera from inmates who had already de-
veloped Aids (Horsburgh et al. 1990). Others, as
the study by Hoxie et al. (1990) carried out be-
tween 1986 and 1988, but published in 1990, con-
centrated its target much more on the relationship
between ingress inmates and intravenous drug us-
ers (IVDUs). Almost at the same time, Vlahov et
al. (1991) carried out one of the most complete
studies among 10,994 ingress inmates in ten dif-
ferent penitentiaries in USA, but the focus was the
IVDUs before confinement and consequently can-
not be compared with our data with regard to al-
most 700 inmates, from two different types of
prison systems, and whose period of study was not
longer than seven months. Similar reports corre-
lating HIV infection among inmates and the IVDUs
have been made in other countries (Rotily et al.
1994, Calzavara et al. 1995).  In addition, reports
of HIV infection among female inmates are rare
(Murphy et al. 1992, Hankins et al. 1994) but the
data are not different from those reported for male
inmates, being the IVDUs the main group of risk,
specially while in jails.
In conclusion, our findings were similar to those
reported more recently in the seroprevalence of
HIV infection among inmates in several parts of
the world. However, the present research has shown
that the inmates from penitentiaries of maximum-
security system, as compared to those from mini-
mum-security ones are more likely to become in-
fected by HIV.
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